Engineering Hybrid Materials with Functional Bioactivity in the GI Tract. This project aims to use an advanced particle engineering approach to develop novel biomaterials with multifunctional activities in the gastrointestinal tract. The project expects to generate new fundamental knowledge of the key interfacial processes that control digestion and identify new pathways for modulating gut microbiome composition. By establishing structure-activity relationships through mechanistic in vitro and i ....Engineering Hybrid Materials with Functional Bioactivity in the GI Tract. This project aims to use an advanced particle engineering approach to develop novel biomaterials with multifunctional activities in the gastrointestinal tract. The project expects to generate new fundamental knowledge of the key interfacial processes that control digestion and identify new pathways for modulating gut microbiome composition. By establishing structure-activity relationships through mechanistic in vitro and in vivo models, the knowledge gain will help guide material design for optimised bioactivity. Technology transfer of the lead formulation through quality by design manufacturing practice is anticipated to position the industry partner for future commercial opportunities within the nutraceutical sector.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC170100016
Funder
Australian Research Council
Funding Amount
$3,123,492.00
Summary
ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therap ....ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therapeutics. The use of an individual patient’s cellular and molecular research findings will ultimately enable personalised diagnostic and therapeutic decisions.Read moreRead less
A novel drug class for the effective treatment of Giardia infections. Companion animals play a pivotal role in the lifestyle of the average Australian family. The 9 million cats and dogs, residing in >65% of our households, have provided significant health and well-being benefits to owners, especially during COVID. Ensuring pet health is a primary obligation of pet ownership. Giardia infections (Giardia duodenalis, with 94% of infections in dogs identified as Assemblage A) is the most prevalent ....A novel drug class for the effective treatment of Giardia infections. Companion animals play a pivotal role in the lifestyle of the average Australian family. The 9 million cats and dogs, residing in >65% of our households, have provided significant health and well-being benefits to owners, especially during COVID. Ensuring pet health is a primary obligation of pet ownership. Giardia infections (Giardia duodenalis, with 94% of infections in dogs identified as Assemblage A) is the most prevalent enteric parasite identified globally in dogs. Infection rates can be as high as 75% in puppies. Current treatments are failing due to poor efficacy, resistance and poor adherence to treatment schedules. We have identified a novel, extremely rapid acting series of compounds capable of single shot eradication of Giardia.Read moreRead less